REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

29/04/2020 16:00

RNS Number : 3749L
  
AstraZeneca PLC
  
29 April 2020
  
 

29 April 2020 16:00 BST
 
Results of Annual General Meeting held on 29 April 2020
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
 







RESOLUTION


VOTES FOR


% OF VOTES CAST


VOTES AGAINST


% OF VOTES CAST


VOTES CAST IN TOTAL 


TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL


VOTES WITHHELD




1


To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019
 


1,061,180,101


99.92


872,215


0.08


1,062,052,316


80.93%


7,121,452




2


To confirm dividends 
 


1,058,995,786


99.10


9,598,531


0.90


1,068,594,317


81.43%


579,469




3


To reappoint PricewaterhouseCoopers LLP as Auditor 
 


1,068,300,235


99.97


312,449


0.03


1,068,612,684


81.43%


560,776




4


To authorise the Directors to agree the remuneration of the Auditor
 


1,067,398,628


99.90


1,086,858


0.10


1,068,485,486


81.42%


687,961




5a


To re-elect Leif Johansson as a Director
 


1,065,113,167


99.69


3,276,071


0.31


1,068,389,238


81.42%


784,805




5b


To re-elect Pascal Soriot as a Director 
 


1,067,248,723


99.90


1,033,124


0.10


1,068,281,847


81.41%


892,364




5c


To re-elect Marc Dunoyer as a Director
 


1,060,164,242


99.25


8,056,265


0.75


1,068,220,507


81.40%


952,979




5d


To re-elect Geneviève Berger as a Director
 


882,846,920


83.06


179,994,848


16.94


1,062,841,768


80.99%


6,331,650




5e


To re-elect Philip Broadley as a Director
 


1,066,048,992


99.79


2,190,705


0.21


1,068,239,697


81.41%


933,713




5f


To re-elect Graham Chipchase as a Director
 


1,062,682,507


99.48


5,520,936


0.52


1,068,203,443


81.40%


969,967




5g


To elect Michel Demaré as a Director
 


1,066,252,259


99.82


1,969,593


0.18


1,068,221,852


81.40%


951,558




5h


To re-elect Deborah DiSanzo as a Director
 


1,067,836,362


99.97


351,091


0.03


1,068,187,453


81.40%


985,957




5i


To re-elect Sheri McCoy as a Director
 


1,064,329,862


99.64


3,890,368


0.36


1,068,220,230


81.40%


951,792




5j


To re-elect Tony Mok as a Director


1,067,117,370


99.90


1,066,669


0.10


1,068,184,039


81.40%


989,371




5k


To re-elect Nazneen Rahman as a Director
 


1,067,376,963


99.92


821,467


0.08


1,068,198,430


81.40%


973,592




5l


To re-elect Marcus Wallenberg as a Director
 


955,082,665


89.42


113,060,725


10.58


1,068,143,390


81.40%


1,030,019




6


To approve the Annual Report on Remuneration for the year ended 31 December 2019
 


1,032,308,145


96.65


35,747,783


3.35


1,068,055,928


81.39%


1,118,038




7


To approve the Directors' Remuneration Policy
 


972,774,742


94.71


54,292,376


5.29


1,027,067,118


78.27%


42,106,679




8


To authorise limited political donations
 


1,038,907,152


97.75


23,872,400


2.25


1,062,779,552


80.99%


6,394,668




9


To authorise the Directors to allot shares
 


910,654,650


85.26


157,472,093


14.74


1,068,126,743


81.40%


1,046,979




10


To authorise the Directors to disapply pre-emption rights
 


1,058,066,972


99.23


8,200,338


0.77


1,066,267,310


81.26%


2,906,339




11


To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
 


1,054,711,677


98.92


11,513,414


1.08


1,066,225,091


81.25%


2,948,557




12


To authorise the Company to purchase its own shares
 


1,051,131,060


98.41


16,950,800


1.59


1,068,081,860


81.39%


1,091,896




13


To reduce the notice period for general meetings
 


998,062,805


93.44


70,101,553


6.56


1,068,164,358


81.40%


1,008,865




14


To approve the 2020 Performance Share Plan


1,010,149,491


95.66


45,877,396


4.34


1,056,026,887


80.48%


13,147,356



 
Issued capital
As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RAGPPURCCUPUGCB